Pyxis Oncology (PYXS) Set to Release Quarterly Earnings on Monday

Key Points

• Pyxis Oncology is expected to report Q3 2026 results before the market opens on Monday, November 2. Analysts forecast a loss of $0.27 per share, with an earnings call scheduled for November 6 at 9:30 a.m. ET.
• The company reported a larger-than-expected Q2 loss of $0.40 per share versus the $0.35 consensus estimate. Analysts project full-year and next-year losses of $1.21 and $1.10 per share, respectively.
• Shares opened at $1.68, well below their 12-month high of $5.55. Despite the decline, eight of 10 analysts rate the stock a Buy, producing a “Moderate Buy” consensus and an average price target of $8.75.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). On average, analysts expect Pyxis Oncology to post ($1.21) EPS for the current fiscal year and ($1.10) EPS for the next fiscal year.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $1.68 on Monday. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55. The company has a market cap of $140.13 million, a price-to-earnings ratio of -1.19 and a beta of 1.37. The business's fifty day simple moving average is $2.80 and its two-hundred day simple moving average is $2.45.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Pyxis Oncology from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Wedbush raised their price objective on Pyxis Oncology from $6.00 to $8.00 and gave the stock an "outperform" rating in a research note on Thursday, September 10th. Wells Fargo & Company lifted their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an "overweight" rating in a research note on Wednesday, September 9th. Weiss Ratings restated a "sell (e+)" rating on shares of Pyxis Oncology in a research note on Friday, September 25th. Finally, Leerink Partners cut their price objective on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating for the company in a research report on Thursday, July 2nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology's pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.